GLP-1 Users Are 70% Less Likely to Develop Dementia

A massive matched cohort study found GLP-1 medication users had a 70% reduced risk of developing dementia compared to non-users. The numbers are striking — here's what the data actually shows.

Alzheimer's disease and related dementias affect over 55 million people worldwide, and that number is projected to hit 150 million by 2050. Effective treatments have been elusive. But a growing body of evidence suggests that medications originally designed for diabetes and obesity may offer unexpected protection for the brain.

A 2025 propensity-matched cohort study using records from 142 healthcare organizations compared 147,505 GLP-1 receptor agonist users against 147,505 matched non-users — and the results were remarkable. J Alzheimers Dis Rep

What the Study Found

The researchers used the TriNetX research platform, which aggregates de-identified electronic health records from healthcare organizations across the country. They identified adults aged 50 and older, comparing those who used GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide, exenatide, albiglutide) against those who didn't.

To ensure a fair comparison, they used propensity-score matching — a statistical technique that balances the two groups on demographics, comorbidities, and other variables that might otherwise skew the results. After matching, each group had 147,505 patients with similar baseline characteristics.

The result: a hazard ratio of 0.30 (95% CI 0.28–0.33, p < 0.001). In plain language, GLP-1 users were 70% less likely to develop dementia during the study period.

How GLP-1s Might Protect the Brain

GLP-1 receptors are expressed on neurons in the central nervous system. When GLP-1 medications activate these receptors, several neuroprotective mechanisms appear to kick in:

Reduced neuroinflammation. Chronic inflammation in the brain is a major driver of Alzheimer's pathology. GLP-1 receptor activation dampens inflammatory pathways in brain tissue, potentially slowing the cascade that leads to neuronal damage.

Improved brain insulin signaling. Insulin resistance in the brain — sometimes called "type 3 diabetes" — is increasingly recognized as a contributor to Alzheimer's disease. GLP-1 medications improve insulin sensitivity in brain tissue.

Reduced amyloid burden. Animal studies have shown that GLP-1 receptor activation reduces the accumulation of amyloid-beta plaques, one of the hallmark features of Alzheimer's disease.

Improved cerebral blood flow. GLP-1 medications improve vascular health throughout the body, including the blood vessels that supply the brain. Better blood flow means better oxygen and nutrient delivery to neurons.

What We Don't Know Yet

It's important to be honest about limitations. This was an observational study, not a randomized controlled trial. While propensity matching helps control for known confounders, there may be unmeasured differences between people who take GLP-1 medications and those who don't.

The EVOKE trials — massive Phase 3 studies testing semaglutide specifically in early Alzheimer's disease — did not show slowing of disease progression in patients who already had the condition. However, there's a critical distinction: prevention is different from treatment. GLP-1 medications may be far more effective at preventing dementia from developing than at reversing it once it's underway.

Ready to Get Started?

These verified telehealth providers offer GLP-1 programs with medical oversight and home delivery:

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or provider selection.